Draft Guidance On Developing Drug Names Calls For Simulation Studies
This article was originally published in The Tan Sheet
Executive Summary
FDA’s draft guidance on developing proprietary drug names recommends steps to evaluate a proposed name, including testing names with health care professionals. The draft notes that OTC “brand name extensions have posed problems when the same root proprietary name is used for multiple products.”
You may also be interested in...
How To Choose A Proprietary Rx Drug Name
US FDA final guidance describes possible study design to test whether selected names may misbrand a drug. Agency also okays use of two-letter USAN stems in product names and clarifies use of modifiers.
Umbrella Branding Is ‘Particular Concern’ As FDA Requests Research Proposals
OTC drugs with single brand for various line extensions might confuse patients, agency says. Findings could have implications for Rx risk communication as well.
Umbrella Branding Is ‘Particular Concern’ As FDA Requests Research Proposals
OTC drugs with single brand for various line extensions might confuse patients, agency says. Findings could have implications for Rx risk communication as well.